Veterinary Medicines

Nobivac Lepto, süstesuspensioon koertele

Not authorised
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated
Download as PDF

Product identification

Medicine name:
Nobivac Lepto, süstesuspensioon koertele
Active substance:
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated
    1500.00
    antigen unit(s)
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated
    1900.00
    antigen unit(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AB01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Estonia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet Nederland B.V.
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 1137
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 27/01/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."